teduglutide + glucose

teduglutide + glucose is an experimental combination being investigated for its effects on lipid metabolism. Teduglutide is a synthetic, degradation-resistant analog of human glucagon-like peptide-2 (GLP-2) that acts as an agonist at the GLP-2 receptor. While teduglutide is primarily approved (under the brand name Gattex) for the treatment of short bowel syndrome to improve intestinal absorption, this specific combination with oral glucose is being studied by the University Health Network to evaluate the plasma lipoprotein response and the release of stored triglycerides from the gut. The research aims to understand how GLP-2 and glucose co-administration modulates postprandial lipidemia in humans, particularly in the context of hyperlipidemia.

Other names

teduglutide and glucose[hGly2]-GLP-2 + glucose